JPS6350328B2 - - Google Patents
Info
- Publication number
- JPS6350328B2 JPS6350328B2 JP53141806A JP14180678A JPS6350328B2 JP S6350328 B2 JPS6350328 B2 JP S6350328B2 JP 53141806 A JP53141806 A JP 53141806A JP 14180678 A JP14180678 A JP 14180678A JP S6350328 B2 JPS6350328 B2 JP S6350328B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ulcer
- administration
- water
- gastric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003699 antiulcer agent Substances 0.000 claims description 6
- 230000002467 anti-pepsin effect Effects 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical compound C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 8
- 208000025865 Ulcer Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 231100000397 ulcer Toxicity 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 229960001138 acetylsalicylic acid Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 210000004051 gastric juice Anatomy 0.000 description 5
- 239000002504 physiological saline solution Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- 206010042220 Stress ulcer Diseases 0.000 description 4
- 230000003444 anaesthetic effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000008602 contraction Effects 0.000 description 4
- 208000000718 duodenal ulcer Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 235000008504 concentrate Nutrition 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003589 local anesthetic agent Substances 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- KCXSWWMGBSTHLT-UHFFFAOYSA-N n-ethyl-6-methoxy-1,2,3,4-tetrahydronaphthalen-2-amine;hydrochloride Chemical compound Cl.COC1=CC=C2CC(NCC)CCC2=C1 KCXSWWMGBSTHLT-UHFFFAOYSA-N 0.000 description 2
- 230000007383 nerve stimulation Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- FOQYDURHXZVLFT-UHFFFAOYSA-N 2-phenyl-2-pyridin-2-ylethanethioamide Chemical compound C=1C=CC=NC=1C(C(=S)N)C1=CC=CC=C1 FOQYDURHXZVLFT-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QWISOXIJIYRLTQ-UHFFFAOYSA-N 6-[ethyl-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)amino]hexyl 3,4-dimethoxybenzoate Chemical compound C1CC2=CC(OC)=CC=C2CC1N(CC)CCCCCCOC(=O)C1=CC=C(OC)C(OC)=C1 QWISOXIJIYRLTQ-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 230000000193 eyeblink Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000011597 hartley guinea pig Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- -1 lithium aluminum hydride Chemical compound 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- OWBFSUWAUCHXEM-UHFFFAOYSA-N n-(6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide Chemical compound C1C(NC(C)=O)CCC2=CC(OC)=CC=C21 OWBFSUWAUCHXEM-UHFFFAOYSA-N 0.000 description 1
- QKGIPGSKJBOHSL-UHFFFAOYSA-N naphthalen-2-amine;hydrochloride Chemical compound [Cl-].C1=CC=CC2=CC([NH3+])=CC=C21 QKGIPGSKJBOHSL-UHFFFAOYSA-N 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000001562 ulcerogenic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14180678A JPS5569511A (en) | 1978-11-17 | 1978-11-17 | Parasympathetic system-blocking agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP14180678A JPS5569511A (en) | 1978-11-17 | 1978-11-17 | Parasympathetic system-blocking agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5569511A JPS5569511A (en) | 1980-05-26 |
| JPS6350328B2 true JPS6350328B2 (en]) | 1988-10-07 |
Family
ID=15300554
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP14180678A Granted JPS5569511A (en) | 1978-11-17 | 1978-11-17 | Parasympathetic system-blocking agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5569511A (en]) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0257486U (en]) * | 1988-10-21 | 1990-04-25 |
-
1978
- 1978-11-17 JP JP14180678A patent/JPS5569511A/ja active Granted
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0257486U (en]) * | 1988-10-21 | 1990-04-25 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5569511A (en) | 1980-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR850000301B1 (ko) | 페닐에탄올 아민 유도체의 제조 방법 | |
| US4066678A (en) | 3-trihydroxygermyl propionic acid and its salts and a process for the production thereof | |
| KR890000380B1 (ko) | 벤조 헤테로사이클 화합물의 제조방법 | |
| RU2104005C1 (ru) | Нервно-мышечный блокатор, его получение, фармацевтический состав и способ обеспечения нервно-мышечной блокады у животных | |
| CA1284953C (en) | 2-alkoxy-n-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides in amethod for alleviating emesis caused by non-platinum anticancer drugs | |
| JPS62255474A (ja) | 抗不整脈剤 | |
| CY1665A (en) | Substituted benzamides | |
| JPS62181246A (ja) | 生体活性ポリペプチド類に対し拮抗活性を有するグルタミン酸類およびアスパラギン酸類の新規酸素化アルキル誘導体およびその製造法 | |
| JPH0122264B2 (en]) | ||
| JPS6350328B2 (en]) | ||
| JPS5914037B2 (ja) | イソキノリン誘導体、その製造方法およびそれを含有する医薬組成物 | |
| US4590210A (en) | Compositions for treatment of ocular hypertension | |
| JPS6310701B2 (en]) | ||
| JPS5940140B2 (ja) | アミノアルコ−ル誘導体及びその製造方法 | |
| KR100510788B1 (ko) | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 | |
| JPH0770082A (ja) | ２−ヒドロキシ−３−〔１−（１ｈ−イミダゾール−４−イル）アルキル〕−ベンゼンカルボキシミダミド | |
| US4128555A (en) | 3-Phenoxypyridine monosulfate and a method for its production | |
| JPH069402A (ja) | 抗潰瘍剤 | |
| JPH0692948A (ja) | 新規なアセタミド誘導体及びその用途 | |
| EP0067910B1 (en) | Compounds and compositions for treatment of ocular hypertension | |
| JPS6228776B2 (en]) | ||
| US3056792A (en) | Unsymmetrical 1, 3-diamino-2-propanols | |
| JPS6234036B2 (en]) | ||
| US4540814A (en) | 1,4-Dimethoxy naphthalenecarboxamide anticonvulsants | |
| JPS6350327B2 (en]) |